Vanda Pharmaceuticals Faces FDA Setback on HETLIOZ® for Jet Lag Disorder Approval Vanda Pharmaceuticals has received a decision letter from the FDA indicating that the supplemental New Drug Application for HETLIOZ® for jet lag disorder cannot be approved in its current form, citing inadequate evidence of efficacy.

Vanda Pharmaceuticals Faces FDA Setback on HETLIOZ® for Jet Lag Disorder Approval #United_States #Washington #Vanda_Pharmaceuticals #Hetlioz #Jet_Lag_Disorder